Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Extended-release of Octreotide (LF-PB) for the Treatment of Seroma
Details : Undisclosed
Product Name : LF-PB
Product Type : Protein
Upfront Cash : Inapplicable
January 29, 2016
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2014
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2014
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 21, 2012
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable